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The incidence of mental retardation is estimated to be 1-3% in the general population, ranging in severity from mild to profound (1) . In most cases the (genetic) basis of this mental retardation is unknown. Among the known causes of mental retarda tion, fragile X syndrome, affecting about 1:1,500 males and 1:2,500 females (2), accoun ts for 50% of the X-linked cases. Fragile X syndrom e has been found in all ethnic groups studied. The identification of the gene involved and the advances in understanding the molecular basis of fragile X syndrome has clarified the unusual pattern of inheritance and has given tools for the identification of patients and carriers.
Fragile X syndro me is associ ated with a fragile site, designated FRAXA, on the long arm of the X chromosome at Xq27.3 in affected individuals. The characteristic microscopic gap in metaphase chromosomes can be induced by culturing cells under conditio ns that influence deoxyn ucleo tide triphosphate levels (3) . Over 100 different fragile sites have been desc ribed, dispersed over different chromosomes (4) , of which only two are now assoc iated with a disease phenotype: FRAXA and FRAXE whic h is located about 600 kb distal from FRAXA (5, 6) . For a number of years confirmation of the clinical diagnosis of fragile X syndrome was carried out by cytogenetic detection of the fragile site in lymphocytes. Most affected males do express the fragile site in 2-50% of the cells . However, the site can be detected in only a proportion of obligate female carriers. Therefore, the cytogenetic test is not reliable in identifying carriers of the fragile X mutati on. In addition two other fragile sites, FRAXE (5) and FRAX F (7), clarified the genetics of fragile X syndrome, and has given tools to establish the diagnosis and to determine carrie r status . (Pediatr Res 38: 629-637, 1995) Abbrevia tio ns SBMA, spinal and bulbar muscular atrophy DRPLA, dentatorubral and pallidoluysian atrophy P CR , polymerase chain reaction located close to FRAXA, may be diagnostically confused with FRAXA .
CLINICAL ASPECTS
In 1943 fragile X syndrome was described by Martin and Bell (8) , who report ed the first pedigree with clear familial mental retardation. The main characteristics of fragil e X males are mental retardation, macroorchidism, large ears, prominent jaw and high-pitched, joc ular speech (Fig. 1) . A delaye d developmen t of speech and language is found but to a variab le degree. There is a large variability in clinical expression of the syndrome, with mental retardation the most common feature . The mental retardation found in these males is varying between moderate and profound. Longitudinal observations indicate a deterioratio n of IQ with age; mental retardation may, for examp le, be moderate at age 12 and severe at age 25. Hyperkinetic behav ior and a problem with conce ntration are present in most affected males. Behaviora l abnormalities also include hand flapping, hand biting, shyn ess, and avoidance of eye contact (9) . A possib le association between fragile X syndrome and autism has been suggested. However, the studies were sma ll in size and Fisch (10) cou ld not establish in a large pooled data set a statistically significan t correlation between fragile X syndrome and autism. The more severe ly retarded males demonstrate a variety of autistic features (9) . Also Reiss and Freund (11) found that 50 -80% of a series of fragile X males meet partial criteria for autism although most did not show significant probl ems in reciprocal interactions with caregivers . Relatively little is know n about structural abnormalities in the brain of fragile X patients. of the hippocampus was enlarged compared with controls (12) . On the other hand Reiss et al. (13, 14) showed that fragile X males showed a significant decreased size of the posterior cerebellar vermis and increased size of the fourth ventricle, when compared with age-and sex-matched groups of fragile X negative, developmentally disabled subjects and individuals with normal IQ.
In Table 1 physical features identified in fragile X males are listed. Macroorchidism is found in about 90% of all affected adult fragile X males and usually develops after puberty (15) . A long and narrow face is often less notable in prepuberal boys, but prominent ears are common in fragile X adults as well as children. Stigmata of connective tissue abnormalities are seen which include finger joint hypermobility and instability of other joints; flat feet were found in more then 50% of the patients.
Two subphenotypes of fragile X syndrome have been described. The features of the Prader-Willi-like phenotype are extreme obesity with a full, round face, small, broad hands and feet, and regional skin hyperpigmentation (16) . Fragile X patients with a Sotos-like phenotype show overgrowth in the first years of life, especially of the head (17) . The cause of the phenotypic variation is unknown.
Females with the fragile X syndrome show some degree of mental impairment, but are less severely affected than males (18) . Females with fragile X syndrome may have behavioral and emotional problems (19) . Typical facial characteristics and hypermobility of finger joints occurred in approximately 40% of adult females, but facial abnormalities were less common in children (20) .
Transmission of the disease within affected families shows an unusual mode of inheritance. In fragile X pedigrees males are predicted to carry the fragile X mutation but are phenotypically normal. These males (termed normal transmitting males) can transmit the mutation to their daughters, who are also unaffected, but grandsons of these males have a risk of exhibiting the full clinical phenotype (the mutation in affected individuals is called full mutation). The risk of having affected offspring to these daughters is 40%, whereas the risk increases in the next generation to 50%. Thus the likelihood of developing fragile X syndrome is dependent upon the position of the individual in the pedigree. This anticipation observed in fragile X families has become known as the Sherman paradox (21, 22) . This paradox could be explained after the responsible gene and the gene defect were determined.
In 1991 the gene involved in fragile X syndrome was cloned using a combination of positional cloning strategies (23) . The FMRI gene was isolated from a cosmid that was covering the fragile site (24) (25) (26) , and the gene consists of 17 exons spanning 38 kb (27) . The gene with an mRNA of 4.8 kb is expressed in most tissues, although to a different extent with high expression in the tissues affected in fragile X syndrome, brain, and adult testes (23, 28, 29) . As a result of alternative splicing at the 3' end of the gene, different mRNA species are made (29, 30) giving rise to many protein isoforms (31, 32) . This may allow functional diversity, but no differences in expression patterns of the mRNA species between different tissues were found. Transgenic mice with a LacZ marker gene driven by the FMRI promoter region of 2.5 kb, which includes the eGG repeats, are crucial for determining the FMRI expression pattern (33) .
The mouse homolog gene Fmr1 was shown to be expressed in several areas of the brain and tubules of the testis in the adult mouse, whereas strong expression was observed in early mouse embryos (28) . The highest level of FMRI expression in brain was observed in neurons, whereas glia cells contained very low levels. In adult testes, FMRI protein was detected only in spermatogonia (32) . The intracellular localization of the FMRI gene products was cytoplasmatic (31, 32) . In the brain of 25-week old fetuses, the gene was expressed in highest levels in cholinergic neurons of the nucleus basalis magnocellularis and in pyramidal neurons of the hippocampus (34) . The early transcription of the gene and the distribution of mRNAs in human fetuses suggest that alterations of FMRI gene expression contributes to the pathogenesis of the fragile X syndrome and especially the mental retardation.
Although originally no strong homology with known genes was found in the predicted FMRI sequence, it was demon- FRAGILE X SYNDRO ME 631 OTHER REPEAT DISEASES Finding heritable unstable triplet repeats at the fragile site led to the speculation that similar repeats might be found in other conditions showing unusual inheritance patterns (56) . A number of genetic disorders involving triplet repeats have been found, although the exact repeat can be different: spinal and bulbar muscular atrophy (SBMA) (57); myotonic dystrophy (58-60); Huntington disease (61); spinocerebellar ataxia type 1 (62); FRAXE mental retardation (6); dentatorubral and pallidoluysian atrophy (DRPLA) (63); Haw River syndrome (64); Machado-Joseph disease (65) . Furthermore, two fragile sites FRA16A and FRAXF, not associated with a disease phenotype, have been found to be caused by repeat amplifications (66, 67) . All of these disorders except one affect neuronal cells as their primary target. In all trinucleotide repeat diseases, there is a threshold length for dynamic mutations of approximately 35 uninterrupted repeats. Amplification of the trinucleotide repeat above the threshold results in extreme instability. As all the repeats show the same threshold length of 35 uninterrupted repeats above which instability occurs, the expansion may be caused by a common mutation mechanism (68) .
The four fragile sites are due to a large expansion of a CGG repeat of more than 200 repeats. The other triplet (CAG/CTG) repeat diseases are not associated with a fragile site, and therefore specific properties of the CGG repeat must be responsible for the induction of the fragile sites. In FRAXA and
BASIS OF THE FRAGILE X MUTATION
In a small number of fragile X syndrome patients who lack the repeat amplification, conventional mutations (point mutations and deletions) have been found in the FMRI gene. These patients either lack the complete gene (46) , part of the gene (47) (48) (49) , or the FMRI promoter region (50) . In a patient with the fragile X phenotype, a point mutation in the FMRI gene has been described in one of the most highly conserved residues of the KH domain (51) . The impairment of the RNA The most interesting feature of the FMRI gene is a repeat binding activity in this patient (52) gives strong evidence for an motif, CGG, present in the first exon (23, 27) . The start codon RNA-binding role of the FMRI protein. However, it is still for translation is found 69 bases after the CGG repeat, indi-unclear what role the FMRI protein is playing in the cell, eating that the repeat is not translated into protein (29) . The especially in the neuron. These mutations support the hypoth-CGG repeat is polymorphic in normal individuals with allele esis that fragile X syndrome is a single gene disorder and that sizes ranging from 6 to 54 repeats (37), with 30 repeats loss of function of the FMRI gene is responsible for the clinical occurring most frequently (38) . Within this normal range, the phenotype of the fragile X syndrom e. alleles are stably inherited. Within fragile X families two
There is strong evidence that the expanded region of CGG classes of unstable repeat numbers are observed. In normal repeats is the fragile site itself. First, fluorescence in situ male carriers and a proportion of female carriers, alleles sizes hybridization localized the fragile site in the proximity of the of between 43 and 200 copies are found which are termed FMR I gene (26) . Second, the fragile site can be seen only premutation sized alleles, because they belong to individuals when the repeat size is above 200 repeats. Third, a positive who carry the disease gene but show no phenotypic effects (37, correlation is found between repeat size and the level of 39). These premutation alleles are meiotically unstable, result-cytogenetic expression (53) . Fourth, a delayed replication of ing in offspring with alleles with a repeat size different from the the repeat has been observed which might give rise to the parental mutation. In clinically affected individuals alleles with configuration that can cause a break at the fragile site (54). repeat sizes above 200 repeats are found. Remarkably, the The CGG repeat in the FMRI gene is possibly a proteinpremutation expands to a full mutation only when transmitted. ,. binging .motif and has been shown to bind a not further by a female; consequently, daughters of normal transmitting characterized protein (55) . This protein is unable to bind to full males have only the premutation allele and never the full mutations as a result of methylation of the repeat sequence. mutation and never show mental retardation or cytogenetic How this lack of binding is affecting the phenotype is unexpression of the fragile site. The risk of expansion to the full known. mutation is correlated with the size of the premutation allele (37) . If the repeat size is small (below 58 repeats), then the risk is of expansion to a full mutation, and thus having an affected child, is very low, and there are no such recorded instances. The risk for a premutation in the range of 59-65 is relative small (20-30%) . If the repeat size is high (>90 repeats) the risk is almost 100% to expand to a full mutation when transmitted. In that case the risk of having a affected child in the next generation due to the chance of inheriting the fragile X chromosome is 50%. On average the risk for a premutation allele to expand to a full mutation is lower then 100%, and this can explain the Sherman paradox which was described earlier.
In front of the FMRI gene a cluster of methylation-sensitive sites was detected (40, 41) . These sites are normally unmethylated and are thought to represent the promoter of the FMRI gene. In fragile X patients these sites are hypermethyl ated as well as the CGG repeat itself (42, 43) . The expression of the FMRI gene was studied in lymphoblastoid cell lines and leukocytes from patients and controls (44, 45) . FMRI mRNA was absent in most male fragile X patients, whereas normal individuals and carriers all showed expression. As a result FMRI proteins are missing in cells of patients not expressing FMRI mRNA (31, 32) . As stated earlier the FMRI protein is binding to RNA and interacts with approximately 4% of human fetal brain message. The absence of the normal interaction of the FMRI protein with a subset of RNA molecules might result in the pleiotropic phenotype associated with the fragile X syndrome.
strated that the protein product of the FMRI gene contains sequence motifs characteristic of RNA-binding proteins: two KH domains and an RGG box (35, 36) . It was shown that in vitro the FMRI protein is binding to a subset of brain mRNA, including its own mRNA. myotonic dystroph y the repeat is not translated into protein and is located in the 5 '-and 3'-untranslated part of the gene, respectively (Fig. 2) . The expansions in these two disorders are very large, with increas es of up to more then 2000 repeats. The largest group of repeat disease are six neurodegenerative conditions listed in group B (Fig. 2) and are caused by an amplified e AG repeat. The repeat expansions in these diseases are relatively small and never exceed 100 repeats. The repeat is translated into a polyglutamine stretch in the protein. Apart from this polyglutamine stretch there is no homology between these genes . Polyglutamine stretches have been found in DNAbinding proteins and expansion of such repeats may alter the biologic role of the protein involved (69, 70) . These altered proteins most likely act in a manner consiste nt with a gain of function, as deletions in the gene causing SBMA do not cause SBMA (57) .
The disorders involving trinucl eotide repeats show genetic anticipation. Anticipation is the term given to the apparent occurrence of increasing severity of symptoms of an inherited disorder (through successive generations) with progressive earlier age of onset of the disease in successive generations. The anticipation seen in fragile X syndrome is an all or nothing phenomenon and does not fit the definition completely. For the other diseases an inverse correlation has been established between repeat length and age of onset.
MECHANISM AND TIMING OF REPEAT AMPLIFICATION
Because affected males rarely reprodu ce, a very high mutation rate has been suggested to maintain the frequency of the disease (71) . However, there is no evidence for any recent mutations in fragile X syndrome; all mothers of males with fragil e X syndrome have been found to be carriers. Richards et at. (72) presente d haplotype evidence for a founder effect in the fragile X mutation. Using microsatellite marker s closely linked to FMR1, they showed linkag e disequilibrium between the disease allele and certain alleles of these markers indicating that a small number of founde r chromosomes are responsible for most of the fragile alleles. In studies of other populations it Gar., Chr.
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. . ,.,.,., -e». . . was also found that allele distributio ns are different on fragile X chromo somes compared with normal X chromo somes, giving furth er support to the suggestion of a fragile X founder effect (73) (74) (75) (76) (77) . The data argue for a limited numb er of independent mutations that provided the origin of most of the present-day fragil e X chromosomes and may expl ain the unexpected long history of some of these fragile X mutations (78, 79) . It was proposed that it may take many generations, maybe up to 100 generations, before a mutati on in a normal allele (most likely starting from chromosomes with repeat length in the upper normal range) results in a full mutation (80, 81) .
In normal alleles the eGG repeat in the FMRl gene is interrupted by one or two AGG triplets leading to impe rfect repeats (82, 83) . Thes e AGG repeats are found at the 5' end of the repeat, whereas most of the length varia tion occurs at the 3 ' end, and here the longest tracts of pure CGGs are found . In premutation alleles this stretch of pure eGGs is increased, and it is postulated that the threshold for instability is about 34 pure eGGs (84) . As longer tracts of e GGs are found only at the 3' end, there appears to be a polarity in the mechanism by which they arise, simil ar to the polarity in the occurrence of new mutations in several human minisatellites (85) . Th e creation of a longer stretch of perfect repeats might be the result of a process of slippage of polymerization during the replication of the DNA leading to relatively small changes (86) . They suggested that, depending on the length of the repeat, one single break is introduced during replic ation of the lagging strand. When this break is the end of an Okazaki fragment, slippage might occur. Anoth er option might be that they have arisen by the loss of AGG triplets from longer interrupted arrays. If the perfect eGG repeat is exceeding the length of an Okazaki fragment (± 150 bases) slippage at both sites of the repeat might occur leading to a rapid expansion to a full mutation (84, 86) .
Daughter s of affected males do not express the fragile X syndrome at either the clinic al or the cytogenetic level (87) . These daughters do have a premutation despite the presence of a full mutation in their fathers. In a study of sperm in four male fragile X patients , Reyniers et at. (88) found that only the premutation was present, although the full mutation was present to the lympho cytes. The most simpl e model to explain the absence of extreme repeat expansion during paternal transmission is that the expression of the FMRl gene is a prerequisite for a prop er germ cell proliferation in the testis and in the ovary (88, 89) . High expressio n has been shown in male germ cells (32, 89, 90) . However, this hypothesis can be ruled out as a male has been described without FMRl protein due to a deletion of the FMRI gene promoter and this man has normal progeny (50) . Also normal fertility of both male and female mice without a proper Fmrl gene indicates that Fmrl is not essential in reproduction (91) . Another selection process could involve delayed replication of expanded repeats (54) . A seco nd model hypothesized that in the germ line cells a premut ation is present and that amplification of the repeat does not occur in meiosis, but that the expansion occurs predominantly early in embryogenesis. This model can explain that the repeat expansion is not uniform: first is the different length of full mutation repeats found in blood cells, which is often shown as a large the activity of the mutant mice was monitored by counting the number of crossings through infrared beams in an empty cage. Mutant mice showe d significantly more crossings, which might indicate hyperactivity, and slower and less efficient learning of the environment. These mutant mice provide a good model in which to study the fragile X syndrome because these transgeni c mice have physic al, mental and behavioral abnormalities comparable to fragile X patients. (Fig. 3) ; second mosaic patients carry the full mutation in some cells as well as a premutation or a deletion of the e GG repeat in some of the cells (92) . However, the pattern of mosaicism was strictly identical in three pairs of monozygotic twins, indicating that the somatic heterogeneity and abnormal meth ylation are established early in development (93).
The FMRI gene was shown to be conserved during evolution and is found in many animal species, even in species as divergent as yeast and Caenorhabditis elegans (23, 29) . The region containing the eGG repeat has also been conserved in many species (94) , which might point to an important regulatory role. The re is marked sequence identity (>97% at the amino acid level) between the murin e homolog and the human gene, including the conservation of the eGG repeat (29) . The ability to generate transgenic mice models by disruption of the murin e FmrI gene has offered the opportunity to get insight into the pathophysiology of human retardation (91) . Like in fragile X patients these mice lack normal Fmrl RNA and protein. No gross pathologic abnormalities were observed in these mice, and the brain anatomy appears to be normal, but these mice have enlarged testes. Interestingly, these mice scored considerably different in behavior studies whe re they scored less well in spatial abilities and showed hyperactivity. An example of a behavior study is given in Fig. 4 . In this test Methods used in DNA diagnosis. The identification of the unstable CGG repeat in the FMRI gene prompted the application of DNA technology for the diagnosis of the fragile X syndrome. Detection of the full mutation in males and females can be routinely carried out by assessi ng the size of restriction enzyme generat ed DNA fragm ents encompassing the CGG repeat (95-100). As the full mutation (F) is characterized by a size increase of the repeat with at least 200 CGG triplets, affected males show fragments exceeding the size of the normal fragment (N) by at least 0.6 kb (Fig. 3) . The DNA patterns of the affected males in the figure illustrate the common features and dissimilarities of full mutations in different individuals. Characteristically, each of the patterns has a diffuse aspect rather than presenting as a discrete band . This implies different degrees of repeat expansion in different cells and is a sign of the somatic instability of the expand ed repeat. Some patients (see Fig. 3 ) show an additional, larger than normal , band well below the full mutation threshold. Phenot ypic differences between these "mosaic" patients and "full mutation only" patients have not been noted (53, 101) .
The full mutation is not only defined by size but also by methylation, which may sometimes act as an independent determinant of the phenotype. Some mild cases without mental impairment have been describ ed with mutations of borderline size or even fully expanded mutations in the absence of (complete) meth ylation (100, 102, 103) . A test for the methylatio n status can be easily combined with Southern analysis by including a digestion with a methylation sensiti ve restriction enzyme.
The patterns observed in females are necess arily more complex due to the presence of the normal X chromosome. The pedigr ee (Fig. 3) shows several carriers of the premutation with affected offspring. The figure illustrates the limits of the method as some of the premutations are barely resolved from the normal X chromo some derived band. An alternative technique is PCR amplification of the CGG repeat (37, 38) . The example in Fig. 3 represents an application of PCR in the presence of radioactively labeled nucleotides, and subsequent size separation and direct autoradiograph y. The figure illustrates the complementary sensitivities of the methods with excellent resolution of premutations after PCR, but with the detection of full mutations restricted to the more laborious Southern blotting method. Although adaptations of the PCR method have been describ ed that do detect the full mutation (38) , most laboratories involved in the diagnosis of fragile X syndrome patients and the detection of carriers use a combination of a PCR-based method and Southern blotting. Of the rarely occurring other mutation s in the FMRl gene, deletions will also be detected using these methods (46) (47) (48) (49) (50) . Only a point mutation , which has been observed once (51), will go unnoticed.
Applications. Obviously, analysis of the FMRl gene in families with an established case of fragile X syndrom e is a prominent application of DNA diagnosis. Female relatives of patients are at increased risk of being a carrier. Whereas cytogenetic analysis of the fragile site at Xq27.3 was known to detect only about 50% of female carriers, DNA analysis reliably discriminat es between female carriers and noncarriers (Fig. 3) .
The occurrence of pedigrees with fragile X syndrome in different branches , which were connect ed through "normal transmitting males" (see Fig. 3 , first generation), has remained unexplained until the identification of the stepwise CGG repeat expansion in the FMRl gene. To date, normal transmitting males are known to inevitably transmit a premutation to all their daughters. Hence, the identification of a male carrier may have widespread consequences, because it may implicitly identify female carriers, who are at risk of having affected children.
Females known to be carrie rs can be offered the possibilit y of prenatal DNA diagnosis. Prenatal DNA analysis can be routinely carried out using a chorionic villus sample, as well as after amniocentesis (38, 97, 104, 105) . The obvious advantage of chorion villi is the early stage of pregnancy. On the other hand methylation tests can be reliably performed on DNA from amniotic fluid cells, which is not possible on chorion villi DNA (97) . The accuracy of the first trimester DNA assay has been shown to be greater than the formerly applied cytogenetic method (97) .
Males with the full mutation are considered to be invariably affected; the situation is more complicated in the case of a female with a full mutation . It has been known for a long time that a proportion of female carriers are mentally retarded. Knowledg e on the repeat expansion has clarified this issue to some degree, as we know now that premutations are not associated with mental impairment (96) . The majority of females (about 60%) carrying the full mutation, however, may be mentally retarded, but to a lesser degree than males with the full mutation (101) . Consequently, the decision whether or not to terminat e a pregnancy of a female fetus with a full mutation may be very difficult and requires delicate counseling. Fig. 3 (last lane) shows an example of first trimester DNA diagnosis. The mother was identified as a carrier of the premutation, and she requested prenatal diagnosis . A normal pattern was obtained with Southern analysis of chorion villusderived DNA of the male fetus. CGG PCR analysis confirmed the diagnosis of an unaffected male by the detection of a single band corresponding in size to the normal maternal allele.
Inasmuch as fragile X syndrome is the most frequent cause of inherited mental retardation, its diagnosis is often considered during diagnostic work up of patients with an otherwise unexplained clinical picture. A study of 525 routine referrals by a genetics center resulted in the identification of 12 (3%) fragile X syndrome patients (106) . Recently, we surveyed a group of patients, who were referred by pediatricians, (child) neurologists, and clinical geneticists, and the range of symptoms of the fragile X syndrome was not consistentl y assessed. Ten unrelated patients (4%) with fragile X syndrome were identified (107) . In these and other (101) studies patients were noted with a full mutation in the absence of expression of the fragile site FRAXA . Apparently, direct detection of the repeat expansion is more sensitive than the cytogenetic method. On the other hand, patients with abnormal karyotypes of a different nature were detected at the same frequency as fragile X patients, which argues strongly in favor of a combination of cytogenetic and DNA diagnosis in cases of unexplained mental retardation (106, 107) .
As was stated earlier, the phenotype of fragile X syndrome is variable, with distinct subtypes, which differ from the Martin Bell phenotype, but which show phenotypic overlap with either Prader-Willi syndrom e or Sotos syndrome (16, 17) . In fact, one of the fragile X patients identified in our diagnosti c study had previously been thought to be affected with Prader-Willi syndrome. Therefore, patients referred for DNA diagnosis of Prader-Willi syndrome, who appear to be negative for the characteristic chromosome IS-related abnormalities, are now routinely tested for fragile X syndrome in our laboratory , as are patients with a Sotos syndrome phenot ype. 
FUTURE DIAGNOSTIC PROSPECTS
There are two prominent reasons, which could favor a wider application of diagnosis of the fragile X syndrome. First, a correct (early) diagnosis provides better opportunities for the patient to receive adequ ate support (9, 108) . Second, finding previou sly unidentified individu als with the syndrome enables couples at risk of having an affected child to make an inform ed reproductiv e choice (109) . In New South Wales, Au stralia, a screening program among intellectuall y handic apped individuals to detect fragil e X syndrome cytogenetically has been operating since 1984. In the (selected) cases where testing was offered , a 79% uptake of the service was reported (109) . A similar positive response rate (87%) among parents of children with speci al education need s in Wessex, UK (110), illustrates the accept ance by the famili es of testing in high risk populations . The numb ers of fragile X patients identified show a strong correlation with the screening criteria. Turn er et al. and was carried out by DNA testing using saliva, which shows the feasibility of this noninvasive protocol in a screening sample of this size.
A much broader target for screening programs would be the general population. Palom aki and Haddow (112) suggested a population-based screenin g for carri ers during pregnancy and the subs equent option of prenatal diagn osis for those identified with a premutation or a full mutation. One of the main arguments against programs aimed at the identification of carrier s is the lack of a clear distinction between large normal alleles and small premutations. Premutations observed in fragile X families are characterized both by increased size and meiotic instability (37) . Based on the frequency of the diseas e, premutations have been estimated earlier to occur on 1:500-1:800 chromosomes in the general population (21, 22) . Estim ations of the actu al allele frequency of PCR-detectable premutation s in the gen eral population have been 1:125 (113) and 1:510 (114), but they are necessarily inaccurate due to limited possibilities to study (in)stability upon transfer to the next generation. Because the frequ ency of stable premutation-sized alleles may be four times higher than the frequency of true premutations (114) , carrier screening programs would generate high numbers of false positives.
A different approach has been prop osed by Young (115) , who suggested to restri ct population screening to a search for full mutations in newborn males. The advantages mentioned are the possibility of an accurate pro gnosis and the offer of testing the extended famil y. Experi enc e with screening newborns for Duchenne 's muscular dystrophy has been reported by Bradley et at. (116) , who se pilot stud y in Wales, UK, has been well recei ved . If screening newborn mal es for fragil e X syndrome were to be considered, new diagn ostic assays hav e to be developed, as the pres ently used DNA technology is fa r too complicated and time consuming for the processing of large numbers of samples.
An alternative assay would be to test the gene product instead of the gen e. As described above, the full mutation is accompanied by silencing of the gen e and, consequently, absence of the protein product FMRP. Recently, an antibody test has been developed, which reliably discriminates between affected and normal males using blood smears of 1-2 drops (117 ) . An exampl e of this test is shown in Fig. 5 . Thi s rapid and inexpensi ve test would be suitable for the scree ning of large numbers of males. Hence, considerations on screening programs may soon be focused on issues of social acceptance and the availability of adequate coun seling faciliti es rather than technical limitations.
